Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06826989 · ClinicalTrials.gov registry record · Phase 1

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06826989 is a Phase 1 study of Healthy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06826989, a Phase 1 study of Healthy, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Conditions Studied

Interventions

  • DRUG [14C]MK-8527

Study Locations (1)

Wisconsin

  • Fortea CRU Madison ( 0001) - Madison

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-03-19
Est. Completion 2025-06-04
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

What the Registry Record Tells You About NCT06826989

The ClinicalTrials.gov registry entry for NCT06826989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [14C]MK-8527 is the first listed.

NCT06826989 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06826989 about?

NCT06826989 is a clinical study titled "A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)". The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

What is the current status of trial NCT06826989?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-03-19. Estimated completion is 2025-06-04.

What conditions does trial NCT06826989 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06826989?

The interventions under investigation include: [14C]MK-8527 (DRUG).

Who is sponsoring clinical trial NCT06826989?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06826989 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.